

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)



(10) International Publication Number
WO 2024/229504 A1

(51) International Patent Classification:
G01N 33/68 (2006.01) *C12N 15/113* (2010.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/AU2023/050959

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:
05 October 2023 (05.10.2023)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2023901363 05 May 2023 (05.05.2023) AU

(71) Applicant: **RAGE BIOTECH PTY LTD** [AU/AU]; Level
35, 360 Elizabeth Street, Melbourne, Victoria 3000 (AU).

(72) Inventors: **THOMAS, Merlin Christopher**; c/- Level
35, 360 Elizabeth Street, Melbourne, Victoria 3000 (AU).
PICKERING, Raelene Jane; c/- Level 35, 360 Elizabeth
Street, Melbourne, Victoria 3000 (AU).

(74) Agent: **FPA PATENT ATTORNEYS PTY LTD**; Level
19, South Tower, 80 Collins Street, Melbourne, Victoria
3000 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS OF MONITORING SPLICING

(57) Abstract: The present invention relates to methods for identifying the splicing of RAGE pre-mRNA resulting in the inclusion of exon 9b and/or exclusion of exon 10 in a subject who has received, or is receiving an antisense oligonucleotide that modulates RAGE pre-mRNA splicing. In one aspect, the present invention provides a method for determining endogenous soluble receptor for advanced glycation end products (RAGE) level in the lung of a subject, the method comprising: determining the presence of endogenous soluble RAGE in a blood sample from a subject who has received or is receiving a treatment administered to their respiratory tract, wherein the treatment increases endogenous soluble RAGE, wherein the level of endogenous soluble RAGE in the blood sample correlates with the endogenous soluble RAGE level in the lung of the subject.



WO 2024/229504 A1